NLRP3 inhibitor found safe, well tolerated in Parkinson’s trial

NLRP3 inhibitor found safe, well tolerated in Parkinson’s trial

Publication date: Jun 24, 2025

The treatment had earlier been found to be well tolerated in healthy volunteers who participated in a Phase 1 study. These included neurofilament light chain and markers of microglial and astrocyte activation, which when elevated are indicators of neurodegeneration. Among such cytokines is interleukin-1 beta, known as IL-1beta.

Concepts Keywords
Biosciences Activation
Inflammationvtx3232 Brain
Parkinson Csf
Running Disease
Yale Il
Inflammatory
Markers
Motor
Nlrp3
Parkinsons
Phase
Tolerated
Treatment
Trial
Ventyx

Semantics

Type Source Name
drug DRUGBANK Methionine
pathway REACTOME Release
disease MESH inflammation
pathway REACTOME The NLRP3 inflammasome
disease MESH neuroinflammation
disease MESH brain inflammation
disease MESH disease progression
disease MESH Movement Disorder
disease MESH obesity
disease MESH risk factors for cardiovascular disease

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *